Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027

Tuesday, March 5, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, March 4, 2019 /PRNewswire/ -- Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027SummaryDownload

the full report: Global sales in the atopic dermatitis market are expected to grow to $18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from 2017-2027. It
is estimated that sales of drugs in the atopic dermatitis market were approximately $6.4B in 2017 in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom and Japan).The US was the largest market, with approximately $5.1B in drug sales, which represented 80% of the total atopic dermatitis market. The 5EU market contributed $1.1B in sales and Japan contributed sales of $202M in 2017. It is forecasted that the US to grow to $13.6B, followed by 5EU (France, Germany, Italy, Spain, United Kingdom) and Japan.Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic factors. The atopic dermatitis market has historically remained stagnant and the pipeline for drugs in late-stage development was lacking, but recent developments have reignited interest in the treatment of the disease, especially as the estimated drug-treated population may grow to 24,000,000 people over the next decade.The atopic dermatitis pipeline has traditionally been focused on topical therapies, with Pfizer's Eucrisa being the latest to be approved in December 2016.Until the launch of Regeneron/Sanofi's Dupixent in March 2017, severe atopic dermatitis patients had to be prescribed systemic immunomodulators, which are associated with a slew of side effects.However, the arrival of Dupixent, a first-in-class monoclonal antibody (mAb), addressed the unmet needs of these severe patients. The pipeline mostly comprises systemic therapies targeting the moderate-to-severe population.The report "Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027", provides key metrics for atopic dermatitis (Epidemiology, Market Size, Product Pipeline, Key Events, Competitive Analysis) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2017-2027.Key Questions Answered- The projected entry of pipeline agents such as the Interleukin inhibitors and the JAK inhibitors during the forecast period is expected to spur intense growth within the atopic dermatitis market. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?- Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the atopic dermatitis indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?- The atopic dermatitis market is likely to remain a dynamic, growing space throughout the forecast period and beyond. Which companies are set to be major players in atopic dermatitis during the forecast period?Scope- Overview of atopic dermatitis including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.- Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the atopic dermatitis therapeutics market.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.- Analysis of the current and future market competition in the global atopic dermatitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Track drug sales in the global atopic dermatitis therapeutics market from 2017-2027.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Download the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +1 (718) 213 4904 Website:

Cision View original content:

SOURCE ReportBuyer

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store